Detection of euglycemic ketoacidosis could be a challenge for physicians since this condition can mask an underlying diabetic ketoacidosis.
Read More »Do SGLT2 Inhibitors Increase the Risk of Acute Kidney Injury?
2016 FDA warning conflicts with recent evidence showing no increased risk following use of treatment.
Read More »Addition of SGLT2 Inhibitor when Glycemic Control Cannot be Attained with Insulin Alone
Benefits of SGLT2 inhibitors in patients treated with insulin.
Read More »Canagliflozin Vs. Dapagliflozin in Type 2 Diabetes
First real-world study comparing SGLT2i therapies also showed patients taking INVOKANA 300 mg significantly less likely to discontinue treatment or switch to another diabetes medicine.
Read More »Which Diabetes Treatment Is Most Effective In Keeping Your Patients Alive?
SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors compared in reducing mortality and cardiovascular events in patients with type 2.
Read More »One More Benefit for SGLT-2 Inhibitors
Treatment method reduced the amount of liver fat more than standard treatment alone.
Read More »Everything You Need to Know to Prescribe an SGLT-2 Inhibitor (Part 2)
Surprise findings for treatment class and appropriate patient selection
Read More »Everything You Need To Know To Prescribe An SGLT-2 Inhibitor (Part 1)
Why and when to use this therapy to treat patients who have type 2 diabetes.
Read More »An SGLT-2 inhibitor Shows Renoprotective Benefits
Subanalysis of CANVAS program shows slower progression of kidney disease, reduction in weight, reduction in A1c and even drop in blood pressure.
Read More »Empagliflozin Reduces Cardiovascular Mortality
Most important mediator due to changes in markers of plasma volume.
Read More »